\-\ Texto\\:\\ \ \(0\)\
\-\ psa\\ levels\\:\\ \\ increasing\\ levels\\ of\\ psa\\ from\\ 15\\.81\\ to\\ 96\\.91\\ during\\ a\\ six\\ month\\ period\\ of\\ time\ \(0\)\
\-\ analgesics\\ for\\ treatment\\ of\\ bone\\ pain\ \(0\)\
\-\ antineoplastic\\ therapy\\ with\\ androgen\\ deprivation\\.\ \(0\)\
\-\ radiation\\ therapy\ \(165\)\
\-\ multiple\\ sclerotic\\ lesions\\ involving\\ the\\ vertebrae\\ and\\ the\\ iliac\\ bones\\ consistent\\ with\\ metastases\\ from\\ prostate\\ cancer\ \(0\)\
\-\ bone\\ metastasis\\ from\\ prostate\\ cancer\\.\ \(0\)\
\-\ bone\\ metastases\\ most\\ commonly\\ from\\ prostate\ \(0\)\
\-\ sclerotic\\ paget\\'s\\-\\ less\\ likely\ \(0\)\
\-\ infection\\,\\ such\\ as\\ tuberculosis\\,\\ unusual\\ without\\ joint\\ space\\ involvement\ \(0\)\
\-\ patient\\ is\\ a\\ 60\\ y\\/o\\ wm\\ with\\ history\\ of\\ prostate\\ ca\\,\\ s\\/p\\ radical\\ prostatectomy\\ with\\ regional\\ lymph\\ node\\ resection\\.\\ \\ patient\\ subsequently\\ underwent\\ 2\\ courses\\ of\\ chemotherapy\\ treatments\\ with\\ response\\.\\ \\ with\\ 3\\ months\\ the\\ patient\\ developed\\ bone\\ metastases\\ from\\ his\\ prostatic\\ carcinoma\\.\\ he\\ is\\ currently\\ enrolled\\ in\\ a\\ trial\\ therapy\\,\\ which\\ requires\\ interval\\ follow\\-up\\ diagnostic\\ imaging\\ study\\ to\\ evaluate\\ response\\ to\\ therapy\\.\ \(0\)\
\-\ metastatic\\ prostate\\ cancer\\ is\\ usually\\ spread\\ hematogenously\\;\\.\\ metastases\\ to\\ bone\\ are\\ the\\ most\\ common\\ metastasis\\ with\\ prostate\\ cancer\\.\\ \\ the\\ proposed\\ hypothesis\\ for\\ this\\ pattern\\ of\\ spread\\ of\\ metastasis\\ is\\ retrograde\\ spread\\ to\\ the\\ axial\\ skeleton\\ \\(pelvis\\ and\\ vertebrae\\)\\ via\\ batson\\â\\€\\™s\\ venous\\ plexus\\,\\ which\\ is\\ a\\ valveless\\ venous\\ plexus\\ of\\ the\\ spine\\ and\\ paraspinal\\ region\\ with\\ communication\\ between\\ the\\ pelvic\\ and\\ vertebral\\ venous\\ systems\\,\\ femoral\\ and\\ iliac\\ veins\\,\\ inferior\\ and\\ superior\\ vena\\ cava\\,\\ and\\ other\\ veins\\.\\ this\\ system\\ may\\ be\\ important\\ for\\ hematogenous\\ spread\\ of\\ either\\ metastases\\ or\\ of\\ microorganisms\\ in\\ spinal\\ infection\\.\\ \\ prostatic\\ metastases\\ are\\ usually\\ osteoblastic\\ as\\ shown\\ on\\ radiographs\\ and\\ on\\ ct\\ images\\.\\ however\\,\\ scintigraphy\\ \\(bone\\ scans\\)\\ are\\ useful\\ for\\ detecting\\ early\\ metastases\\ several\\ weeks\\ or\\ months\\ before\\ the\\ radiographs\\ become\\ abnormal\\.\\ \\ \\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ the\\ increase\\ in\\ public\\ awareness\\ of\\ prostate\\ cancer\\ and\\ in\\ the\\ use\\ of\\ psa\\ to\\ screen\\ for\\ the\\ disease\\ has\\ led\\ to\\ early\\ diagnosis\\ and\\ treatment\\ of\\ prostate\\ cancer\\.prior\\ to\\ 1991\\,\\ greater\\ than\\ 30\\%\\ of\\ patients\\ developed\\ distant\\ metastases\\ currently\\ approximately\\ 6\\%\\ have\\ metastases\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ prostate\\:\\ 0\\.4084445210373854\ \(0\)\
\-\ metastases\\:\\ 0\\.3835255554276816\ \(0\)\
\-\ cancer\\:\\ 0\\.21065574524177882\ \(0\)\
\-\ psa\\:\\ 0\\.19197913966531183\ \(0\)\
\-\ spread\\:\\ 0\\.18940465495814787\ \(0\)\
\-\ bone\\:\\ 0\\.17256477291279393\ \(0\)\
\-\ of\\:\\ 0\\.1444144870649014\ \(0\)\
\-\ prostatic\\:\\ 0\\.13016283654458433\ \(0\)\
\-\ the\\:\\ 0\\.12621318958093175\ \(0\)\
\-\ therapy\\:\\ 0\\.12114368323160611\ \(0\)\
\-\ metastasis\\:\\ 0\\.11589992979532929\ \(0\)\
\-\ venous\\:\\ 0\\.11290009358933488\ \(0\)\
\-\ vertebrae\\:\\ 0\\.10910499845260704\ \(0\)\
\-\ and\\:\\ 0\\.10892094547685212\ \(0\)\
\-\ to\\:\\ 0\\.10542128526807262\ \(0\)\
\-\ from\\:\\ 0\\.10467298521240542\ \(0\)\
\-\ response\\:\\ 0\\.09724292319899601\ \(0\)\
\-\ iliac\\:\\ 0\\.09704940353711519\ \(0\)\
\-\ plexus\\:\\ 0\\.09504457723867293\ \(0\)\
\-\ veins\\:\\ 0\\.09355202993041689\ \(0\)\
\-\ sclerotic\\:\\ 0\\.08843561842120506\ \(0\)\
\-\ valveless\\:\\ 0\\.08429645504646072\ \(0\)\
\-\ levels\\:\\ 0\\.08357758599952234\ \(0\)\
\-\ with\\:\\ 0\\.08257187124943463\ \(0\)\
\-\ currently\\:\\ 0\\.080982541896711\ \(0\)\
\-\ for\\:\\ 0\\.07988158387112645\ \(0\)\
\-\ developed\\:\\ 0\\.0782145691260542\ \(0\)\
\-\ deprivation\\:\\ 0\\.07789144278840453\ \(0\)\
\-\ batson\\:\\ 0\\.07789144278840453\ \(0\)\
\-\ microorganisms\\:\\ 0\\.07789144278840453\ \(0\)\
\-\ early\\:\\ 0\\.07599156544513788\ \(0\)\
\-\ prostatectomy\\:\\ 0\\.07582948939443832\ \(0\)\
\-\ hematogenously\\:\\ 0\\.07582948939443832\ \(0\)\
\-\ androgen\\:\\ 0\\.07414475080078234\ \(0\)\
\-\ enrolled\\:\\ 0\\.07414475080078234\ \(0\)\
\-\ public\\:\\ 0\\.0727203246160236\ \(0\)\
\-\ is\\:\\ 0\\.07217640511368374\ \(0\)\
\-\ hypothesis\\:\\ 0\\.06854376538123787\ \(0\)\
\-\ radiographs\\:\\ 0\\.0683753839493788\ \(0\)\
\-\ usually\\:\\ 0\\.06636712646136522\ \(0\)\
\-\ awareness\\:\\ 0\\.06631531235796741\ \(0\)\
\-\ infection\\:\\ 0\\.06368105671100925\ \(0\)\
\-\ 1991\\:\\ 0\\.062138753123181685\ \(0\)\
\-\ months\\:\\ 0\\.0613641991950079\ \(0\)\
\-\ courses\\:\\ 0\\.06133472628466996\ \(0\)\
\-\ proposed\\:\\ 0\\.060957511484359704\ \(0\)\
\-\ detecting\\:\\ 0\\.060957511484359704\ \(0\)\
\-\ are\\:\\ 0\\.060004346307833724\ \(0\)\
\-\ hematogenous\\:\\ 0\\.05991030009991122\ \(0\)\
\-\ wm\\:\\ 0\\.05896977920767225\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.05896977920767225\ \(0\)\
\-\ regional\\:\\ 0\\.05867640601423598\ \(0\)\
\-\ trial\\:\\ 0\\.05867640601423598\ \(0\)\
\-\ radical\\:\\ 0\\.058392061135559475\ \(0\)\
\-\ skeleton\\:\\ 0\\.057334854639891436\ \(0\)\
\-\ led\\:\\ 0\\.05684840130394684\ \(0\)\
\-\ retrograde\\:\\ 0\\.056386281041764595\ \(0\)\
\-\ communication\\:\\ 0\\.055322985267838944\ \(0\)\
\-\ distant\\:\\ 0\\.05512425762105941\ \(0\)\
\-\ most\\:\\ 0\\.054864860245575076\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.054739181927530266\ \(0\)\
\-\ treatments\\:\\ 0\\.05455249922630352\ \(0\)\
\-\ screen\\:\\ 0\\.05436951345628093\ \(0\)\
\-\ in\\:\\ 0\\.05245120096015908\ \(0\)\
\-\ patient\\:\\ 0\\.05143278186192789\ \(0\)\
\-\ paraspinal\\:\\ 0\\.051312261620143705\ \(0\)\
\-\ requires\\:\\ 0\\.05105556512967317\ \(0\)\
\-\ systems\\:\\ 0\\.05092984238183525\ \(0\)\
\-\ vena\\:\\ 0\\.05092984238183525\ \(0\)\
\-\ cava\\:\\ 0\\.050683414993464244\ \(0\)\
\-\ useful\\:\\ 0\\.050325674340343976\ \(0\)\
\-\ treatment\\:\\ 0\\.050218146579648085\ \(0\)\
\-\ which\\:\\ 0\\.04793648395053191\ \(0\)\
\-\ interval\\:\\ 0\\.04769664246026659\ \(0\)\
\-\ six\\:\\ 0\\.04735116373953697\ \(0\)\
\-\ unusual\\:\\ 0\\.04726677521310308\ \(0\)\
\-\ become\\:\\ 0\\.046776014965208446\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.04638606345795883\ \(0\)\
\-\ period\\:\\ 0\\.04608553357428111\ \(0\)\
\-\ scans\\:\\ 0\\.045866381498123616\ \(0\)\
\-\ node\\:\\ 0\\.04530618092779076\ \(0\)\
\-\ ca\\:\\ 0\\.04497255337538102\ \(0\)\
\-\ subsequently\\:\\ 0\\.04497255337538102\ \(0\)\
\-\ important\\:\\ 0\\.04465055287161699\ \(0\)\
\-\ either\\:\\ 0\\.043576256525652224\ \(0\)\
\-\ via\\:\\ 0\\.04308258237241316\ \(0\)\
\-\ before\\:\\ 0\\.042613950603075726\ \(0\)\
\-\ bones\\:\\ 0\\.042413062703937666\ \(0\)\
\-\ as\\:\\ 0\\.04235180450029714\ \(0\)\
\-\ increase\\:\\ 0\\.042314233104947044\ \(0\)\
\-\ increasing\\:\\ 0\\.04151430313168599\ \(0\)\
\-\ pelvic\\:\\ 0\\.041204042063756496\ \(0\)\
\-\ lymph\\:\\ 0\\.040988636519178924\ \(0\)\
\-\ evaluate\\:\\ 0\\.040988636519178924\ \(0\)\
\-\ shown\\:\\ 0\\.0408617629550469\ \(0\)\
\-\ use\\:\\ 0\\.04033125864837063\ \(0\)\
\-\ vertebral\\:\\ 0\\.040252279710980804\ \(0\)\
\-\ system\\:\\ 0\\.040213041947472924\ \(0\)\
\-\ diagnostic\\:\\ 0\\.040173970094665584\ \(0\)\
\-\ 60\\:\\ 0\\.0394253439335346\ \(0\)\
\-\ pattern\\:\\ 0\\.03935371195139811\ \(0\)\
\-\ femoral\\:\\ 0\\.039177024361390915\ \(0\)\
\-\ commonly\\:\\ 0\\.0390036519319026\ \(0\)\
\-\ greater\\:\\ 0\\.03883347254702247\ \(0\)\
\-\ involvement\\:\\ 0\\.0381510885535067\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.037428337558041785\ \(0\)\
\-\ spinal\\:\\ 0\\.037428337558041785\ \(0\)\
\-\ involving\\:\\ 0\\.03692111075499393\ \(0\)\
\-\ pelvis\\:\\ 0\\.036866433202432325\ \(0\)\
\-\ or\\:\\ 0\\.03667447613198173\ \(0\)\
\-\ underwent\\:\\ 0\\.03631104412891297\ \(0\)\
\-\ this\\:\\ 0\\.03622493672664474\ \(0\)\
\-\ 30\\:\\ 0\\.035958503520624095\ \(0\)\
\-\ less\\:\\ 0\\.03586019962093223\ \(0\)\
\-\ inferior\\:\\ 0\\.03586019962093223\ \(0\)\
\-\ study\\:\\ 0\\.03515447668211238\ \(0\)\
\-\ space\\:\\ 0\\.03508678055940027\ \(0\)\
\-\ spine\\:\\ 0\\.034820849129702625\ \(0\)\
\-\ joint\\:\\ 0\\.0347338792696218\ \(0\)\
\-\ several\\:\\ 0\\.03458362426112274\ \(0\)\
\-\ superior\\:\\ 0\\.03426964798351774\ \(0\)\
\-\ between\\:\\ 0\\.03424909073494674\ \(0\)\
\-\ such\\:\\ 0\\.03390643828107552\ \(0\)\
\-\ resection\\:\\ 0\\.03378847311191269\ \(0\)\
\-\ approximately\\:\\ 0\\.03363349288499976\ \(0\)\
\-\ during\\:\\ 0\\.03338706549662875\ \(0\)\
\-\ month\\:\\ 0\\.03206474509576344\ \(0\)\
\-\ his\\:\\ 0\\.031967985264823015\ \(0\)\
\-\ on\\:\\ 0\\.031839287846070104\ \(0\)\
\-\ abnormal\\:\\ 0\\.031668097103387395\ \(0\)\
\-\ weeks\\:\\ 0\\.03159077046451276\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03152937170425542\ \(0\)\
\-\ region\\:\\ 0\\.03152937170425542\ \(0\)\
\-\ likely\\:\\ 0\\.03149882463702664\ \(0\)\
\-\ time\\:\\ 0\\.03124317261077957\ \(0\)\
\-\ he\\:\\ 0\\.031213555664202506\ \(0\)\
\-\ however\\:\\ 0\\.0311987827123405\ \(0\)\
\-\ axial\\:\\ 0\\.030447801959712598\ \(0\)\
\-\ lesions\\:\\ 0\\.030272557856300782\ \(0\)\
\-\ common\\:\\ 0\\.029893206775915927\ \(0\)\
\-\ than\\:\\ 0\\.029880399456580133\ \(0\)\
\-\ patients\\:\\ 0\\.029652852213700464\ \(0\)\
\-\ metastatic\\:\\ 0\\.028909377823985706\ \(0\)\
\-\ consistent\\:\\ 0\\.02858114502658612\ \(0\)\
\-\ without\\:\\ 0\\.027803100673942156\ \(0\)\
\-\ imaging\\:\\ 0\\.027701444209512077\ \(0\)\
\-\ other\\:\\ 0\\.027373698064336083\ \(0\)\
\-\ diagnosis\\:\\ 0\\.027325038239297442\ \(0\)\
\-\ may\\:\\ 0\\.02652586586867858\ \(0\)\
\-\ have\\:\\ 0\\.02633206415367789\ \(0\)\
\-\ multiple\\:\\ 0\\.025782125082924323\ \(0\)\
\-\ images\\:\\ 0\\.02438237309018696\ \(0\)\
\-\ has\\:\\ 0\\.02407687487280716\ \(0\)\
\-\ disease\\:\\ 0\\.02212622906800526\ \(0\)\
\-\ be\\:\\ 0\\.021382768468599763\ \(0\)\
\-\ history\\:\\ 0\\.020138675177229556\ \(0\)\
\-\ ct\\:\\ 0\\.020067594215795483\ \(0\)\
\-\ pain\\:\\ 0\\.018861955957545053\ \(0\)\
